Elacytarabine is a fatty acid derivative of cytarabine, an approved cytotoxic cancer drug. Cytarabine has limitations such as minimal uptake in solid tumours and is only used to treat leukaemia.... Elacytarabine is designed to overcome this limitation and has shown considerable uptake in solid tumour cells.
- Mechanism
- Curator reviewed
CP-4055 is the lipophilic 5'-elaidic acid ester of the deoxycytidine analog cytosine arabinoside (cytarabine; Ara-C) with potential antineoplastic activity. As a prodrug, CP-4055 is converted intracellularly into cytarabine triphosphate by deoxycytidine kinase and subsequently competes with cytidine for incorporation into DNA, thereby inhibiting DNA synthesis. Compared to cytarabine, CP-4055 shows increased cellular uptake and retention, resulting in increased activation by deoxycytidine kinase to cytarabine triphosphate, decreased deamination and deactivation by deoxycytidine deaminase, and increased inhibition of DNA synthesis. This agent also inhibits RNA synthesis, an effect not seen with cytarabine.
- Primary indication
- Investigated for use/treatment in leukemia (unspecified) and melanoma.Curator reviewed
- Formula / weight
- C27H45N3O6 · 507.672 g/mol (avg)
- Code names
- CP-4055 · P-4055
Resolves to
FLFGNMFWNBOBGE-FNNZEKJRSA-NSMILESCCCCCCCC\C=C\CCCCCCCC(=O)OC[C@H]1O[C@H]([C@@H](O)[C@@H]1O)N1C=CC(N)=NC1=OWhat you can answer from here — as of January 14, 2023
Which drugs share a target with Elacytarabine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account